+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

C

Actively Recruiting

This research aims to evaluate the effects of TAK-330 compared to standard four-factor prothrombin complex concentrate 4F-PCC in adults treated with Factor Xa inhibitors who need urgent surgery or invasive procedures. The study focuses on reversing anticoagulation caused by Factor Xa inhibitors and is a Phase 3, randomized, triple-blind trial sponsored by Takeda. Participants will be randomly assigned to receive either TAK-330 or the standard 4F-PCC. TAK-330 is given as a single intravenous infusion dose of 25 IUkg before surgery, with an optional additional 25 IUkg dose during surgery if needed, not exceeding a total of 50 IUkg or 5,000 IU. The standard 4F-PCC dose and infusion speed follow local protocols, with an additional dose allowed during surgery under the same maximum limits. These treatments are administered during hospitalization prior to surgery. During the study, participants will be hospitalized for the surgery and treatment administration, with assessments of hemostasis effectiveness at surgery end and 24 hours after treatment. Researchers will monitor blood product use, adverse events including thrombotic events, and participant survival up to 30 days after surgery. Follow-up will also include contact via telehealth or phone 30 days post-surgery to evaluate safety and outcomes. Total participation duration covers the hospital stay and the 30-day post-surgery monitoring period.

Age: 18Years +All GendersPhase 3
64 locations
R

Actively Recruiting

Researchers are evaluating the human monoclonal antibody NG004 in patients with acute traumatic incomplete cervical spinal cord injury SCI. This randomized, double-blind, placebo-controlled, multicenter Phase 1 trial aims to assess the safety, tolerability, pharmacokinetics, and effects on motor function and daily life functioning of NG004 compared to placebo. The study focuses on patients who have sustained an incomplete cervical SCI within 4 to 28 days prior to enrollment. Participants receive repeated intrathecal injections of either NG004 or placebo within 30 days. This treatment period involves carefully controlled administration of the study drug or placebo directly into the spinal fluid. The trial includes two groups one receiving NG004 and the other receiving placebo, allowing comparison of the effects on neurological recovery and daily functioning. During the trial, participants undergo evaluations of adverse events and drug reactions from treatment start up to 6 months. Motor function changes are measured using the International Standards for Neurological Classification of Spinal Cord Injury protocol, and daily life independence is assessed with the Spinal Cord Independence Measure at 6 months. Safety monitoring and drug concentration measurements in serum and cerebrospinal fluid are performed throughout this period to understand the treatments impact and tolerability.

Age: 18Years - 75YearsAll GendersPhase 1
10 locations
P

Actively Recruiting

Researchers are conducting a multicentre phase III clinical trial involving adults and adolescents aged 12 years and older who have severe burns. The study aims to confirm the effectiveness and function of denovoSkin, an autologous dermo-epidermal skin substitute, in achieving wound closure and reducing scarring for patients with deep partial and full-thickness burns compared to the standard treatment of split-thickness skin grafts. Participants receive either the experimental treatment with denovoSkin applied to one burn area or the standard split-thickness skin graft STSG applied to another area. The study uses an intra-patient randomized design where one location is treated with denovoSkin and the other with STSG, with the roles of locations A and B switched among participants. This design allows direct comparison of the two treatments in the same patient. During the trial, participants are monitored for wound closure and scar quality six months after grafting, which is the primary outcome. Secondary outcomes include assessment of graft take, epithelialization, scar contracture, and donor site healing at various time points up to 24 months post-grafting. Participants will undergo regular evaluations to measure these outcomes and ensure safety, with the study lasting until 2029.

Age: 12Years +All GendersPhase 3
19 locations